Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Starpharma Holdings Ltd. (OTC: SPHRY).

Full DD Report for SPHRY

You must become a subscriber to view this report.


Recent News from (OTC: SPHRY)

Starpharma Licenses VivaGel® BV to Mundipharma for Europe
Starpharma licenses VivaGel ® BV to Mundipharma for Europe, Russia, CIS 1 and the balance of Latin America to be marketed as part of the popular BETADINE ® Feminine Care portfolio Deal terms include a financially attractive revenue share; in addition to an u...
Source: Business Wire
Date: June, 26 2018 19:49
Starpharma Presentation Now Available for On-Demand Viewing
Starpharma Presentation Now Available for On-Demand Viewing Canada NewsWire NEW YORK, April 16, 2018 NEW YORK , April 16, 2018 /CNW/ -- Virtual Investor Conferences today announced that the April 12 Starpharma (ASX: SPL, OTCQX: SPHRY) presentation by Chief Exe...
Source: Canada Newswire
Date: April, 16 2018 16:22
Starpharma (SPHRY) Presents At OTCQX International Virtual Investor Conference - Slideshow
The following slide deck was published by Starpharma Holdings Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 13 2018 13:37
Starpharma to present at OTCQX Virtual Investor Conference
Starpharma to present at OTCQX Virtual Investor Conference Canada NewsWire MELBOURNE, Australia, April 11, 2018 MELBOURNE, Australia , April 11, 2018 /CNW/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-re...
Source: Canada Newswire
Date: April, 11 2018 08:42
OTC Markets Group Announces the 2018 OTCQX Best 50
NEW YORK , Jan. 24, 2018 /PRNewswire/ --  OTC Markets Group Inc. (OTCQX: OTCM), operator of the OTCQX®, OTCQB® and Pink® financial markets for 10,000 U.S. and global securities, today announced the 2018 OTCQX® Best 50, a ranking of top performing OTCQX companies ...
Source: PR Newswire
Date: January, 24 2018 07:00
Starpharma: NDA Submission for VivaGel® BV in the US
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its US New Drug Application (NDA) submission for VivaGel ® BV for both treatment and prevention of BV has been lodged with the FDA through a rolling submission process. VivaGel ® BV has been granted Fast Track status an...
Source: Business Wire
Date: November, 21 2017 08:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1110.3910.3910.3910.391,000
2018-12-1010.0510.0510.0510.05750
2018-12-0710.2810.2810.2810.28200
2018-12-0610.8810.8810.8810.881,022
2018-12-05N/A11.75N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-065001,02248.9237Short
2018-12-032001,47613.5501Cover
2018-11-3010015066.6667Short
2018-11-29508505.8824Cover
2018-11-273755,8456.4157Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SPHRY.


About Starpharma Holdings Ltd. (OTC: SPHRY)

Logo for Starpharma Holdings Ltd. (OTC: SPHRY)

Starpharma Holdings Limited ASX:SPL, OTCQX:SPHRY is a global biopharmaceutical company based in Australia with established commercial partnerships and products launched, or nearing launch, within the pharmaceutical and sexual health sectors. Starpharma has developed a diverse portfolio of compelling products based on an underlying technology built around dendrimers. Starpharma s most advanced products are based on VivaGel SPL , astodrimer sodium , a proprietary dendrimer which has antimicrobial properties. VivaGel has been developed as two discrete products for bacterial vaginosis BV , firstly for the treatment of BV, and secondly, for the prevention of recurrent BV. These breakthrough products target areas of significant unmet medical need in high value markets. The VivaGel range includes the world s first and only antiviral condom licensed to several partners . Starpharma revolutionary DEP technology is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP versions of existing drugs, particularly in the area of anti cancer. DEP partnerships include multiple programs with AstraZeneca and other world leading pharmaceutical companies. Starpharma has an IP portfolio of patents. The Starpharma HQ and research facilities are located in Melbourne Australia.

 

 

 

Current Management

  • Dr. Jackie Fairley / CEO, IR, Managing Director
    • Dr Jackie Fairley has more than years of operational experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding now Pfizer . She was appointed Chief Executive Officer of the group in July . Jackie holds first class honours degrees in Science pharmacology and pathology and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in . Whilst at CSL she obtained an MBA from the Melbourne Business School where, as Dux of her final year, she was the recipient of the prestigious Clemenger Medal and a number of other academic prizes. Jackie is a Graduate of the Australian Institute of Company Directors. Jackie currently sits on the board of the Melbourne Business School and is a member of the Government s Commonwealth Science Council, and is a past member of the Federal Government s Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She is also an advisor to the Carnegie Innovation Fund.
  • Nigel Baade / CFO, Secretary
  • Robert Thomas / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Richard Hazleton / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Mr Hazleton is a former Chairman and CEO of USbased global corporation Dow Corning. He joined Dow Corning in and held numerous positions in engineering, manufacturing and finance, both in the US and Europe. He was appointed as Chief Executive Officer of the company in , and Chairman of the Board of Directors and CEO in . During his career with Dow Corning, Mr Hazleton performed the roles of European Area Vice President and Director of Finance and later Corporate Controller and Chief Accounting Officer. In this latter global role he was responsible for the preparation of all public financial reports, and relationships with financial regulatory agencies and independent auditors. Mr Hazleton retired from Dow Corning in . Mr Hazleton has served on the boards of the American Chemistry Council and the Chemical Bank and Trust Company Midland, MI, USA as well as several nonprofit social service agencies in Michigan and Belgium.
  • Zita Peach / Independent Director, Compensation Committee Member, Nominating Committee Member
  • Peter Turvey / Independent Director, Audit Committee Member

Current Share Structure

  • Market Cap: $397,561,766 - 03/09/2018
  • Issue and Outstanding: 370,514,227 - 10/12/2017

 



Daily Technical Chart for (OTC: SPHRY)

Daily Technical Chart for (OTC: SPHRY)


Stay tuned for daily updates and more on (OTC: SPHRY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SPHRY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SPHRY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SPHRY and does not buy, sell, or trade any shares of SPHRY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/